3D Printing: Move beyond the hype and discover its true commercial value
3D printing has the potential to impact the entire product lifecycle. No longer just the darling of R&D departments, this fledgling technology is extending its reach. Although experts agree it’s not a panacea, it certainly can’t be ignored either. What difference is 3D printing making now? What developments are expected? And what is the single biggest factor that could seriously hamper further progress if pharma doesn’t lay the right foundations today?
The Future of 3D Printing in Pharma cuts through the hype and identifies where the tangible value can be gained from this emerging technology. Insights are drawn from interviews with 8 experts from pharmaceutical and technology companies and institutes at the forefront of these ground-breaking new developments.
Report available for immediate download -- place your order today
Clearly there is little point in innovation for its own sake. 3D printing has been of interest in pharma R&D departments for a while, but now others are also taking notice – and for good reason. 3D printing may well be the catalyst that transforms the drug manufacturing landscape forever, not only in terms of how drugs are manufactured and administered but also in key areas such as speed to market, cost and personalisation. As the technology is now so accessible, the question for pharma companies is not ‘should you be involved?’, it’s ‘why wouldn’t you?’
Find answers to these and many more important questions — download the report today
“What's interesting about 3D printing is the crossover point where it becomes economically as well as technically interesting. The next question is, will it be clinically and commercially successful? Of course, that's not a given with any product.”
Clive Roberts, University of Nottingham, UK
“It is conceivable that a pharmacy in the future would in fact be able to print pills itself and that would, of course, change the structure of the industry considerably. The pharmaceutical company would then be the pill developer and designer but not the manufacturer. There could be shift from a centralised to a decentralised manufacturing model.”
Adam Cohen, Additive Insight LLC, USA
“It’s my belief that the development of 3D printing for use in the printing of medicines will require multiple parties to collaborate.”
Martin Wallace, GlaxoSmithKline
Critical insights from these and many other respected experts available for immediate download —place your order here
Report available for immediate download — place your order here
This critical intelligence is available for immediate download —order your copy here
Need more information? Contact a consultant for an executive summary and sample pages from the report.
3D Printing: Move beyond the hype and discover its true commercial value
3D printing has the potential to impact the entire product lifecycle. No longer just the darling of R&D departments, this fledgling technology is extending its reach. Although experts agree it’s not a panacea, it certainly can’t be ignored either. What difference is 3D printing making now? What developments are expected? And what is the single biggest factor that could seriously hamper further progress if pharma doesn’t lay the right foundations today?
The Future of 3D Printing in Pharma cuts through the hype and identifies where the tangible value can be gained from this emerging technology. Insights are drawn from interviews with 8 experts from pharmaceutical and technology companies and institutes at the forefront of these ground-breaking new developments.
Report available for immediate download -- place your order today
Clearly there is little point in innovation for its own sake. 3D printing has been of interest in pharma R&D departments for a while, but now others are also taking notice – and for good reason. 3D printing may well be the catalyst that transforms the drug manufacturing landscape forever, not only in terms of how drugs are manufactured and administered but also in key areas such as speed to market, cost and personalisation. As the technology is now so accessible, the question for pharma companies is not ‘should you be involved?’, it’s ‘why wouldn’t you?’
Find answers to these and many more important questions — download the report today
“What's interesting about 3D printing is the crossover point where it becomes economically as well as technically interesting. The next question is, will it be clinically and commercially successful? Of course, that's not a given with any product.”
Clive Roberts, University of Nottingham, UK
Critical insights from these and many other respected experts available for immediate download —place your order here
Report available for immediate download — place your order here
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved